Читать книгу Genome Editing in Drug Discovery - Группа авторов - Страница 19

1 Acharya, S., Mishra, A., Paul, D. et al. (2019). Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing. Proc. Natl. Acad. Sci. U. S. A. 116: 20959–20968.

2 Anzalone, A.V., Randolph, P.B., Davis, J.R. et al. (2019). Search‐and‐replace genome editing without double‐strand breaks or donor DNA. Nature 576: 149–157.

3 Batta, A., Kalra, B.S., and Khirasaria, R. (2020). Trends in FDA drug approvals over last 2 decades: an observational study. J Family Med Prim Care 9: 105–114.

4 Behan, F.M., Iorio, F., Picco, G. et al. (2019). Prioritization of cancer therapeutic targets using CRISPR‐Cas9 screens. Nature 568: 511–516.

5 Bibikova, M., Carroll, D., Segal, D.J. et al. (2001). Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell Biol. 21: 289–297.

6 Boch, J., Scholze, H., Schornack, S. et al. (2009). Breaking the code of DNA binding specificity of TAL‐type III effectors. Science 326: 1509–1512.

7 Chen, J.S., Ma, E., Harrington, L.B. et al. (2018). CRISPR‐Cas12a target binding unleashes indiscriminate single‐stranded DNase activity. Science 360: 436–439.

8 Cong, L., Ran, F.A., Cox, D. et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819–823.

9 Cui, Y., Cheng, X., Chen, Q. et al. (2021). CRISP‐view: a database of functional genetic screens spanning multiple phenotypes. Nucleic. Acids. Res. 49 (D1): D848–D854.

10 Doench, J.G. (2018). Am I ready for CRISPR? A user's guide to genetic screens. Nat. Rev. Genet. 19: 67–80.

11 Fellmann, C., Gowen, B.G., Lin, P.C. et al. (2017). Cornerstones of CRISPR‐Cas in drug discovery and therapy. Nat. Rev. Drug Discov. 16: 89–100.

12 Gilbert, L.A., Horlbeck, M.A., Adamson, B. et al. (2014). Genome‐scale CRISPR‐mediated control of gene repression and activation. Cell 159: 647–661.

13 Gootenberg, J.S., Abudayyeh, O.O., Kellner, M.J. et al. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360: 439–444.

14 Jinek, M., Chylinski, K., Fonfara, I. et al. (2012). A programmable dual‐RNA‐guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816–821.

15 Kampmann, M. (2018). CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine. ACS Chem. Biol. 13: 406–416.

16 Kim, Y.G., Cha, J., and Chandrasegaran, S. (1996). Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U. S. A. 93: 1156–1160.

17 Lancaster, M.A., Renner, M., Martin, C.A. et al. (2013). Cerebral organoids model human brain development and microcephaly. Nature 501: 373–379.

18 Liu, X., Zhang, Y., Cheng, C. et al. (2017). CRISPR‐Cas9‐mediated multiplex gene editing in CAR‐T cells. Cell Res. 27: 154–157.

19 Lundin, A., Porritt, M.J., Jaiswal, H. et al. (2020). Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre‐clinical cancer drug discovery. Nat. Commun. 11: 4903.

20 Mali, P., Yang, L., Esvelt, K.M. et al. (2013). RNA‐guided human genome engineering via Cas9. Science 339: 823–826.

21 Morgan, P., Brown, D.G., Lennard, S. et al. (2018). Impact of a five‐dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17: 167–181.

22 Moscou, M.J. and Bogdanove, A.J. (2009). A simple cipher governs DNA recognition by TAL effectors. Science 326: 1501.

23 Myhrvold, C., Freije, C.A., Gootenberg, J.S. et al. (2018). Field‐deployable viral diagnostics using CRISPR‐Cas13. Science 360: 444–448.

24 Rees, H.A. and Liu, D.R. (2018). Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19: 770–788.

25 Vamathevan, J., Clark, D., Czodrowski, P. et al. (2019). Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18: 463–477.

26 Wiedenheft, B., Sternberg, S.H., and Doudna, J.A. (2012). RNA‐guided genetic silencing systems in bacteria and archaea. Nature 482: 331–338.